Belite Bio (BLTE) News Today $62.50 -0.16 (-0.26%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$63.30 +0.80 (+1.28%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume - Time to Buy?Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume - Still a Buy?May 1, 2025 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Shares Purchased by JPMorgan Chase & Co.JPMorgan Chase & Co. increased its holdings in shares of Belite Bio, Inc (NASDAQ:BLTE - Free Report) by 130.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,636 shares of the company's stock after acquiring anApril 30, 2025 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Sees Significant Drop in Short InterestBelite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the target of a significant decrease in short interest in March. As of March 31st, there was short interest totalling 70,000 shares, a decrease of 21.5% from the March 15th total of 89,200 shares. Based on an average daily trading volume, of 42,500 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.3% of the company's stock are sold short.April 21, 2025 | marketbeat.comLeerink Partnrs Expects Reduced Earnings for Belite BioBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Leerink Partnrs reduced their FY2028 earnings per share estimates for Belite Bio in a research note issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $4.40 for the year, downApril 18, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Stock Price Down 7.2% - Time to Sell?Belite Bio (NASDAQ:BLTE) Trading Down 7.2% - Here's WhyApril 11, 2025 | marketbeat.comBelite Bio, Inc. Appoints New AuditorMarch 28, 2025 | tipranks.comBelite Bio price target raised to $80 from $79 at BenchmarkMarch 27, 2025 | markets.businessinsider.comBelite Bio (NASDAQ:BLTE) Shares Gap Up - Here's What HappenedBelite Bio (NASDAQ:BLTE) Shares Gap Up - What's Next?March 27, 2025 | marketbeat.comBenchmark Reiterates Buy Rating for Belite Bio (NASDAQ:BLTE)Benchmark reissued a "buy" rating and issued a $80.00 target price on shares of Belite Bio in a research note on Wednesday.March 27, 2025 | marketbeat.comFY2025 EPS Forecast for Belite Bio Decreased by AnalystBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of Belite Bio in a research note issued on Tuesday, March 18th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings per share of ($1.36) for the yMarch 21, 2025 | marketbeat.comEquities Analysts Issue Forecasts for Belite Bio Q1 EarningsBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Research analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for Belite Bio in a report issued on Tuesday, March 18th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.37) per sharMarch 21, 2025 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Short Interest UpdateBelite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 81,300 shares, a growth of 17.1% from the February 13th total of 69,400 shares. Based on an average trading volume of 46,300 shares, the days-to-cover ratio is currently 1.8 days. Currently, 0.3% of the company's stock are sold short.March 20, 2025 | marketbeat.comBelite Bio's (BLTE) "Overweight" Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Belite Bio in a report on Tuesday.March 19, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Belite Bio in a research note on Tuesday.March 19, 2025 | marketbeat.comPromising Pipeline and Strategic Advancements: Marc Goodman Recommends ‘Buy’ for Belite Bio, Inc.March 19, 2025 | tipranks.comBelite Bio (NASDAQ:BLTE) Shares Gap Down on Disappointing EarningsBelite Bio (NASDAQ:BLTE) Shares Gap Down After Earnings MissMarch 18, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPSBelite Bio (NASDAQ:BLTE - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02).March 18, 2025 | marketbeat.comBelite Bio Advances in Retinal Disease Trials and Financial PositionMarch 18, 2025 | tipranks.comBelite Bio, Inc. (BLTE) Q4 2024 Earnings Call TranscriptMarch 17, 2025 | seekingalpha.comBelite Bio reports Q4 EPS (32c), consensus (31c)March 17, 2025 | markets.businessinsider.comBelite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 17, 2025 | globenewswire.comBelite Bio Announces Availability of Annual Report on Form 20-FÂ Through Company WebsiteMarch 17, 2025 | globenewswire.comBelite Bio Reports 2024 Financial Results and Clinical ProgressMarch 17, 2025 | tipranks.comBelite Bio (NASDAQ:BLTE) Stock Price Down 1.6% - What's Next?Belite Bio (NASDAQ:BLTE) Shares Down 1.6% - Here's What HappenedMarch 15, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - Here's WhyBelite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - What's Next?March 12, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Stock Price Up 4.8% - Here's What HappenedBelite Bio (NASDAQ:BLTE) Trading 4.8% Higher - Here's What HappenedMarch 11, 2025 | marketbeat.comBelite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comBelite Bio (NASDAQ:BLTE) Trading Up 3.9% - Time to Buy?Belite Bio (NASDAQ:BLTE) Stock Price Up 3.9% - Should You Buy?March 4, 2025 | marketbeat.comBelite Bio to Participate in the Leerink Partners Global Healthcare ConferenceMarch 4, 2025 | tmcnet.comBelite Bio, Inc. ADR (BLTE) Gets a Buy from Benchmark Co.March 3, 2025 | markets.businessinsider.comBelite Bio (BLTE) Expected to Announce Quarterly Earnings on MondayBelite Bio (NASDAQ:BLTE) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports.March 3, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume - Should You Buy?Belite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - Here's What HappenedMarch 1, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Shares Gap Up - Should You Buy?Belite Bio (NASDAQ:BLTE) Shares Gap Up - Here's WhyFebruary 28, 2025 | marketbeat.comPromising Phase 3 Results for Belite Bio’s Tinlarebant in Stargardt Disease Boost Buy RatingFebruary 28, 2025 | tipranks.comBelite Bio announces interim results from DRAGON trialFebruary 27, 2025 | markets.businessinsider.comBelite Bio’s Phase 3 Trial for Stargardt Disease Drug AdvancesFebruary 27, 2025 | tipranks.comBelite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease SubjectsFebruary 27, 2025 | finance.yahoo.comBelite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume - Still a Buy?Belite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - Still a Buy?February 22, 2025 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.2% in JanuaryBelite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 63,800 shares, a drop of 9.2% from the January 15th total of 70,300 shares. Based on an average trading volume of 59,400 shares, the days-to-cover ratio is currently 1.1 days.February 17, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Trading Up 7.8% - Here's What HappenedBelite Bio (NASDAQ:BLTE) Trading Up 7.8% - Here's What HappenedFebruary 11, 2025 | marketbeat.comBelite Bio (NASDAQ:BLTE) Trading Down 4.7% - Should You Sell?Belite Bio (NASDAQ:BLTE) Shares Down 4.7% - Here's What HappenedFebruary 10, 2025 | marketbeat.comBelite Bio to sell 258,309 shares at $58.07 in registered direct offeringFebruary 6, 2025 | markets.businessinsider.comBelite Bio: The Picture Is Still UnclearFebruary 6, 2025 | seekingalpha.comBelite Bio Announces Registered Direct Offering of $15 MillionFebruary 5, 2025 | globenewswire.comBelite Bio FY2024 EPS Forecast Lifted by Leerink PartnrsBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Investment analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Belite Bio in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings ofJanuary 31, 2025 | marketbeat.comJPMorgan Chase & Co. Grows Stock Holdings in Belite Bio, Inc (NASDAQ:BLTE)JPMorgan Chase & Co. increased its holdings in shares of Belite Bio, Inc (NASDAQ:BLTE - Free Report) by 7,122.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,356 shares of the company's stock afterJanuary 31, 2025 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Short Interest Down 60.3% in JanuaryBelite Bio, Inc (NASDAQ:BLTE - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 80,400 shares, a drop of 60.3% from the December 31st total of 202,300 shares. Based on an average daily volume of 72,900 shares, the short-interest ratio is currently 1.1 days.January 29, 2025 | marketbeat.comBelite Bio files automatic mixed securities shelfJanuary 29, 2025 | markets.businessinsider.comBelite Bio (NASDAQ:BLTE) Shares Gap Up on Analyst UpgradeBelite Bio (NASDAQ:BLTE) Shares Gap Up After Analyst UpgradeJanuary 22, 2025 | marketbeat.comCantor Fitzgerald Forecasts Belite Bio FY2025 EarningsBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Belite Bio in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim forecasts that the company will post earnings ofJanuary 22, 2025 | marketbeat.com Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address BLTE Media Mentions By Week BLTE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLTE News Sentiment▼1.070.72▲Average Medical News Sentiment BLTE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLTE Articles This Week▼22▲BLTE Articles Average Week Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LNTH News BBIO News TGTX News LEGN News SRPT News TLX News ADMA News BPMC News VRNA News NUVL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLTE) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BLTE Stock Free BLTE Stock Alerts